Your browser is no longer supported. Please, upgrade your browser.
Freeline Therapeutics Holdings plc
Index- P/E- EPS (ttm)- Insider Own8.23% Shs Outstand35.68M Perf Week-6.52%
Market Cap135.59M Forward P/E- EPS next Y-3.07 Insider Trans0.00% Shs Float34.74M Perf Month14.42%
Income- PEG- EPS next Q-1.00 Inst Own32.60% Short Float0.22% Perf Quarter-56.63%
Sales- P/S- EPS this Y-73.10% Inst Trans-3.78% Short Ratio0.17 Perf Half Y-74.03%
Book/sh5.20 P/B0.72 EPS next Y16.80% ROA- Target Price- Perf Year-78.31%
Cash/sh4.53 P/C0.82 EPS next 5Y- ROE- 52W Range2.92 - 18.88 Perf YTD-79.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.61% Beta-
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin- 52W Low31.85% ATR0.33
Employees236 Current Ratio12.20 Sales Q/Q- Oper. Margin- RSI (14)44.84 Volatility6.73% 7.99%
OptionableNo Debt/Eq1.00 EPS Q/Q- Profit Margin- Rel Volume0.17 Prev Close3.73
ShortableYes LT Debt/Eq1.00 EarningsAug 16 BMO Payout- Avg Volume460.89K Price3.85
Recom2.00 SMA20-0.08% SMA50-12.34% SMA200-65.45% Volume78,286 Change3.22%
Aug-17-21Downgrade JP Morgan Overweight → Neutral
May-19-21Initiated H.C. Wainwright Buy $30
May-06-21Initiated Guggenheim Buy $17
Mar-23-21Initiated Mizuho Buy $27
Mar-02-21Initiated Stifel Buy $21
Sep-09-21 07:00AM  
Sep-07-21 07:00AM  
Aug-17-21 08:29AM  
Aug-16-21 07:00AM  
Aug-13-21 06:30AM  
Jun-30-21 04:01PM  
Jun-22-21 10:34PM  
Jun-16-21 07:00AM  
May-26-21 11:06AM  
May-17-21 04:02PM  
May-12-21 07:00AM  
May-11-21 07:00AM  
Apr-27-21 04:31PM  
Apr-21-21 04:01PM  
Mar-31-21 04:02PM  
Mar-30-21 04:01PM  
Mar-11-21 07:00AM  
Mar-02-21 07:00AM  
Feb-18-21 03:11AM  
Feb-16-21 07:00AM  
Feb-09-21 07:30AM  
Feb-08-21 04:01PM  
Jan-26-21 07:00AM  
Jan-04-21 07:00AM  
Dec-14-20 07:00AM  
Dec-11-20 12:01AM  
Nov-19-20 07:00AM  
Nov-13-20 06:37AM  
Nov-02-20 07:00AM  
Oct-30-20 07:00AM  
Oct-29-20 04:15PM  
Sep-29-20 07:00AM  
Sep-28-20 07:00AM  
Sep-25-20 07:00AM  
Sep-23-20 07:00AM  
Sep-14-20 12:02PM  
Sep-10-20 07:00AM  
Aug-07-20 02:49AM  
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.